FCMI
MNTA

Foresite Capital Management III’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Foresite Capital Management III’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-430,632
Closed -$5.75M – 33
2017
Q1 		$5.75M Buy
+430,632
New +$6.74M 2.21% 11
2016
Q4 		– Sell
-595,513
Closed -$6.96M – 23
2016
Q3 		$6.96M Buy
+595,513
New +$7M 3.25% 8

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Foresite Capital Management III's MNTA Position: Q2 2017 in Review

Foresite Capital Management III sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2017, closing a stake of 430,632 shares — an estimated $5.75M sold.

Foresite Capital Management III first reported a position in MNTA in Q3 2016 and held it in 2 quarters. The position peaked at $6.96M in Q3 2016. 164 funds tracked by Wall St. Rank hold MNTA as of Q2 2017.

  • Foresite Capital Management III reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Foresite Capital Management III sold 430,632 Momenta Pharmaceuticals, Inc. shares in Q2 2017, an estimated $5.75M.
  • Foresite Capital Management III first reported a position in Momenta Pharmaceuticals, Inc. in Q3 2016 and held it in 2 quarters.
  • Foresite Capital Management III's Momenta Pharmaceuticals, Inc. position peaked at $6.96M in Q3 2016.
  • 164 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2017.

Based on Foresite Capital Management III's 13F filing for Q2 2017, filed 14 Aug 2017.